CP1-Derived Peptides for Selective Complement Pathway Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for autoimmune and inflammatory diseases mediated by dysregulated complement activation are limited, particularly for common conditions, and there is a need for specific regulators that can inhibit the classical and lectin pathways without affecting the alternative pathway.
Innovation Solution
Development of peptide compounds derived from human astrovirus coat protein, such as CP1, which can bind and inactivate C1q and MBL to regulate the classical and lectin pathways, with modifications like deletions, substitutions, and acetylation to enhance efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current anti-complement therapies (C1-Inhibitor, Eculizumab) are used, then complement activation is inhibited, but they are limited to orphan diseases and not applicable to common autoimmune and inflammatory conditions
Solution Approach 1:
The patent modifies the molecular parameters of complement regulators by creating peptide compounds with specific amino acid sequences (e.g., Compstatin, C1q-binding peptides) that have altered binding affinities and specificities. These parameter changes enable the peptides to selectively inhibit classical and lectin pathways while preserving alternative pathway function, expanding applicability to common autoimmune diseases.
Solution Approach 2:
The patent segments the complement system inhibition into pathway-specific regulators: Compstatin for alternative pathway, and separate peptide compounds for classical and lectin pathways. This segmentation allows selective targeting of specific pathways involved in different diseases, improving both specificity and adaptability to various autoimmune conditions.
2Object-affected harmful factors
If broad-spectrum complement inhibitors are used, then all complement pathways are suppressed, but this causes excessive immune suppression and failure to preserve protective functions
Solution Approach 1:
The patent applies local quality by creating pathway-specific peptide regulators with distinct binding specificities: Compstatin binds C3 to regulate alternative pathway, while other peptides bind C1q or MBL to regulate classical and lectin pathways. This localized regulation at specific pathway nodes prevents harmful tissue damage while preserving protective immune functions in other pathways.
Solution Approach 2:
The patent uses peptide compounds as intermediary regulators that mediate selective complement inhibition. These peptides act as molecular intermediaries between the complement system and the immune response, providing precise control over specific pathways without broad suppression, thus balancing protection and prevention of tissue damage.
3Manufacturing precision
If peptide compounds with high binding affinity to C1q and MBL are designed, then classical and lectin pathways are effectively inhibited, but the peptides may cross-react with alternative pathway components
Solution Approach 1:
The patent employs parameter changes by systematically varying amino acid sequences, lengths, and structural features of the peptide compounds. This allows optimization of binding affinity and specificity parameters to achieve high selectivity for C1q and MBL while avoiding cross-reactivity with alternative pathway components, ensuring reliable pathway-specific inhibition.
Solution Approach 2:
The patent uses copying by creating peptide analogs and mutants of natural complement regulators (e.g., analogs of C1-Inhibitor or astrovirus coat protein). These copied peptides retain beneficial binding properties while being engineered to avoid off-target effects, improving both manufacturing precision and reliability through iterative optimization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide compounds effectively inhibit classical and lectin pathway activation, providing therapeutic benefits for diseases like rheumatoid arthritis, lupus erythematosus, and hereditary angioedema, while preserving the alternative pathway's immune function.
Implementation Method 1
peptide compounds that can bind, regulate and inactivate C1 and MBL
Data Source
AI summary
The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.